23. Clinicopathological and mammographic features of the triple-negative breast cancer
Main Article Content
Abstract
Triple-negative breast cancer is a rare subtype with a poor prognosisThe purpose of this study was to describe clinicopathological and mammographic features in 34 patients with triple-negative breast cancer from 01/01/2022 to 31/05/2022 at the K hospital. The mean age of patients was 57.5 years old. Most lesions (82.4%) had a high grade on pathology. Invasive ductal breast cancer with no special type was the most prevalent (79.4%). On mammography, most of the triple-negative breast cancer was detected as a mass (about 80%) with an irregular shape and an obscure or microlobulated margin (approximately 30%). Detected tumours were rarely classified as BIRADS 5 (9.4%), but one-third were classified as BIRADS 3. Tumours with pathological high grade had a higher rate of masses with circumscribe or obscure margin and BIRADS 3 classification was higher compared to tumours with mild and intermediate grades. Triple-negative breast cancer can acquire characteristics with low suspicion of malignancy, which may lead to misdiagnosis as a benign lesion.
Article Details
Keywords
Breast cancer, triple-negative breast cancer, mammography, molecular breast cancer subtype
References
1. Tan PH, Ellis I, Allison K, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020; 77(2): 181-185. doi:10.1111/his.14091.
2. Jackisch C, Harbeck N, Huober J, et al. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus – Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care. 2015; 10(3): 211-219. doi:10.1159/000433590.
3. Hennigs A, Riedel F, Gondos A, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer. 2016; 16:734. doi:10.1186/s12885-016-2766-3.
4. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol Off J Eur Soc Med Oncol. 2011; 22(8): 1736-1747. doi:10.1093/annonc/mdr304.
5. Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast Edinb Scotl. 2015; 24 Suppl 2: S26-35. doi:10.1016/j.breast.2015.07.008.
6. Yao K, Goldschmidt R, Turk M, et al. Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups. Breast Cancer Res Treat. 2015; 154(1): 81-88. doi:10.1007/s10549-015-3587-9.
7. Greer LT, Rosman M, Mylander WC, et al. Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens? J Am Coll Surg. 2013; 216(2): 239-251. doi:10.1016/j.jamcollsurg.2012.09.007.
8. Dershaw DD, Morris EA, Liberman L, Abramson AF. Nondiagnostic stereotaxic core breast biopsy: results of rebiopsy. Radiology. 1996; 198(2): 323-325. doi:10.1148/radiology.198.2.8596825.
9. Krizmanich-Conniff K, Paramagul C, Patterson SK, et al. Triple Negative Breast Cancer: Imaging and Clinical Characteristics. AJR Am J Roentgenol. 2012; 199(2): 458-464. doi:10.2214/AJR.10.6096.
10. Elfgen C, Varga Z, Reeve K, et al. The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay. Breast Cancer Res Treat. 2019; 177(1): 67-75. doi:10.1007/s10549-019-05298-6.
11. Trần Thị Hoài, Lê Hồng Quang, Nguyễn Ngọc Tú, Đoàn Thị Hồng Nhật. Kết quả điều trị bệnh nhân ung thư vú bộ ba âm tính giai đoạn I - III tại Bệnh viện Ung bướu Nghệ An. Tạp chí học Việt Nam. 2022; 518(1). doi:10.51298/vmj.v518i1.3380.
12. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. 2007; 13(15 Pt 1): 4429-4434. doi:10.1158/1078-0432.CCR-06-3045.
13. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007; 109(9): 1721-1728. doi:10.1002/cncr.22618.
14. Hussain S, Durrani F, Khan A. Frequency and Clinicopathologic Characteristics of Triple-Negative Breast Cancer Among Breast Cancer Patients Presenting to Medical Oncology Department, Hayatabad Medical Complex Peshawar, Pakistan. Cureus. 15(2): e34581. doi:10.7759/cureus.34581.
15. Abdou Y, Gupta M, Asaoka M, et al. Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer. Sci Rep. 2022; 12(1): 13377. doi:10.1038/s41598-022-16749-4.
16. Nguyễn ThịTuyền, Huệ, Hồ Thị Nguyên Sa, Nguyễn Văn Thanh, Lê Ngọc Ánh. Đặc điểm mô bệnh học ung thư vú có bộ ba dấu ấn hoá mô miễn dịch âm tính tại Bệnh viện Ung bướu Đà Nẵng. Tạp chí Dược học Cần Thơ. 2023; (58): 187-193. doi:10.58490/ctump.2023i58.710.
17. Gao B, Zhang H, Zhang SD, et al. Mammographic and clinicopathological features of triple-negative breast cancer. Br J Radiol. 2014; 87(1039): 20130496. doi:10.1259/bjr.20130496.
18. Yang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. 2008; 111(3): 405-410. doi:10.1007/s10549-007-9810-6.
19. Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA. Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol. 2010; 20(5): 1111-1117. doi:10.1007/s00330-009-1656-3.
20. Breast Imaging Reporting & Data System. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Bi-Rads. Accessed September 26, 2023.
21. Boisserie-Lacroix M, Mac Grogan G, Debled M, et al. Radiological features of triple-negative breast cancers (73 cases). Diagn Interv Imaging. 2012; 93(3): 183-190. doi:10.1016/j.diii.2012.01.006.
22. Tan PS, Ali MA, Eriksson M, Hall P, Humphreys K, Czene K. Mammography features for early markers of aggressive breast cancer subtypes and tumor characteristics: A population-based cohort study. Int J Cancer. 2021; 148(6): 1351-1359. doi:10.1002/ijc.33309.
23. Baré M, Torà N, Salas D, et al. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program. Breast Cancer Res Treat. 2015; 154(2): 403-415. doi:10.1007/s10549-015-3623-9.
24. Boisserie-Lacroix M, MacGrogan G, Debled M, et al. Triple-Negative Breast Cancers: Associations Between Imaging and Pathological Findings for Triple-Negative Tumors Compared With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Breast Cancers. The Oncologist. 2013; 18(7): 802-811. doi:10.1634/theoncologist.2013-0380.
25. Shin HJ, Kim HH, Huh MO, et al. Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer. Br J Radiol. 2011; 84(997): 19-30. doi:10.1259/bjr/92960562.
2. Jackisch C, Harbeck N, Huober J, et al. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus – Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care. 2015; 10(3): 211-219. doi:10.1159/000433590.
3. Hennigs A, Riedel F, Gondos A, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer. 2016; 16:734. doi:10.1186/s12885-016-2766-3.
4. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol Off J Eur Soc Med Oncol. 2011; 22(8): 1736-1747. doi:10.1093/annonc/mdr304.
5. Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast Edinb Scotl. 2015; 24 Suppl 2: S26-35. doi:10.1016/j.breast.2015.07.008.
6. Yao K, Goldschmidt R, Turk M, et al. Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups. Breast Cancer Res Treat. 2015; 154(1): 81-88. doi:10.1007/s10549-015-3587-9.
7. Greer LT, Rosman M, Mylander WC, et al. Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens? J Am Coll Surg. 2013; 216(2): 239-251. doi:10.1016/j.jamcollsurg.2012.09.007.
8. Dershaw DD, Morris EA, Liberman L, Abramson AF. Nondiagnostic stereotaxic core breast biopsy: results of rebiopsy. Radiology. 1996; 198(2): 323-325. doi:10.1148/radiology.198.2.8596825.
9. Krizmanich-Conniff K, Paramagul C, Patterson SK, et al. Triple Negative Breast Cancer: Imaging and Clinical Characteristics. AJR Am J Roentgenol. 2012; 199(2): 458-464. doi:10.2214/AJR.10.6096.
10. Elfgen C, Varga Z, Reeve K, et al. The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay. Breast Cancer Res Treat. 2019; 177(1): 67-75. doi:10.1007/s10549-019-05298-6.
11. Trần Thị Hoài, Lê Hồng Quang, Nguyễn Ngọc Tú, Đoàn Thị Hồng Nhật. Kết quả điều trị bệnh nhân ung thư vú bộ ba âm tính giai đoạn I - III tại Bệnh viện Ung bướu Nghệ An. Tạp chí học Việt Nam. 2022; 518(1). doi:10.51298/vmj.v518i1.3380.
12. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. 2007; 13(15 Pt 1): 4429-4434. doi:10.1158/1078-0432.CCR-06-3045.
13. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007; 109(9): 1721-1728. doi:10.1002/cncr.22618.
14. Hussain S, Durrani F, Khan A. Frequency and Clinicopathologic Characteristics of Triple-Negative Breast Cancer Among Breast Cancer Patients Presenting to Medical Oncology Department, Hayatabad Medical Complex Peshawar, Pakistan. Cureus. 15(2): e34581. doi:10.7759/cureus.34581.
15. Abdou Y, Gupta M, Asaoka M, et al. Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer. Sci Rep. 2022; 12(1): 13377. doi:10.1038/s41598-022-16749-4.
16. Nguyễn ThịTuyền, Huệ, Hồ Thị Nguyên Sa, Nguyễn Văn Thanh, Lê Ngọc Ánh. Đặc điểm mô bệnh học ung thư vú có bộ ba dấu ấn hoá mô miễn dịch âm tính tại Bệnh viện Ung bướu Đà Nẵng. Tạp chí Dược học Cần Thơ. 2023; (58): 187-193. doi:10.58490/ctump.2023i58.710.
17. Gao B, Zhang H, Zhang SD, et al. Mammographic and clinicopathological features of triple-negative breast cancer. Br J Radiol. 2014; 87(1039): 20130496. doi:10.1259/bjr.20130496.
18. Yang WT, Dryden M, Broglio K, et al. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. 2008; 111(3): 405-410. doi:10.1007/s10549-007-9810-6.
19. Ko ES, Lee BH, Kim HA, Noh WC, Kim MS, Lee SA. Triple-negative breast cancer: correlation between imaging and pathological findings. Eur Radiol. 2010; 20(5): 1111-1117. doi:10.1007/s00330-009-1656-3.
20. Breast Imaging Reporting & Data System. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Bi-Rads. Accessed September 26, 2023.
21. Boisserie-Lacroix M, Mac Grogan G, Debled M, et al. Radiological features of triple-negative breast cancers (73 cases). Diagn Interv Imaging. 2012; 93(3): 183-190. doi:10.1016/j.diii.2012.01.006.
22. Tan PS, Ali MA, Eriksson M, Hall P, Humphreys K, Czene K. Mammography features for early markers of aggressive breast cancer subtypes and tumor characteristics: A population-based cohort study. Int J Cancer. 2021; 148(6): 1351-1359. doi:10.1002/ijc.33309.
23. Baré M, Torà N, Salas D, et al. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program. Breast Cancer Res Treat. 2015; 154(2): 403-415. doi:10.1007/s10549-015-3623-9.
24. Boisserie-Lacroix M, MacGrogan G, Debled M, et al. Triple-Negative Breast Cancers: Associations Between Imaging and Pathological Findings for Triple-Negative Tumors Compared With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Breast Cancers. The Oncologist. 2013; 18(7): 802-811. doi:10.1634/theoncologist.2013-0380.
25. Shin HJ, Kim HH, Huh MO, et al. Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer. Br J Radiol. 2011; 84(997): 19-30. doi:10.1259/bjr/92960562.